Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.
FDA application actionOctober 10, 2024
Aflibercept
Approved submission · SUPPL 6
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 9, 2024
Everolimus
Approved submission · SUPPL 6
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 9, 2024
Everolimus
Approved submission · SUPPL 7
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 9, 2024
Everolimus
Approved submission · SUPPL 8
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 4, 2024
Everolimus
Approved submission · SUPPL 8
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionOctober 4, 2024
Everolimus
Approved submission · SUPPL 9
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 16, 2024
Sirolimus
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionSeptember 11, 2024
Busulfan
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 31, 2024
Fezolinetant
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 22, 2024
hydrochlorothiazide
Approved submission · SUPPL 14
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionAugust 15, 2024
propofol
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 31, 2024
Dasatinib
Approved submission · SUPPL 28
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 31, 2024
Dasatinib
Approved submission · SUPPL 4
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJuly 22, 2024
Busulfan
Approved submission · SUPPL 6
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 25, 2024
Busulfan
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 20, 2024
propofol
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 12, 2024
Acyclovir
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 12, 2024
Dapagliflozin
Approved submission · SUPPL 31
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionJune 12, 2024
Dapagliflozin
Approved submission · SUPPL 22
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionApril 30, 2024
hydrochlorothiazide
Approved submission · SUPPL 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionApril 30, 2024
hydrochlorothiazide
Approved submission · SUPPL 2
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionApril 30, 2024
Everolimus
Approved submission · SUPPL 6
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionApril 9, 2024
Everolimus
Approved submission · SUPPL 10
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionApril 4, 2024
Sirolimus
Approved submission · SUPPL 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →